{"id":177750,"date":"2026-01-26T22:39:02","date_gmt":"2026-01-27T03:39:02","guid":{"rendered":"https:\/\/alphastreet.com\/india\/?p=177750"},"modified":"2026-01-26T22:39:02","modified_gmt":"2026-01-27T03:39:02","slug":"innova-captab-limited-accelerating-strategic-growth-with-strong-q3-and-9-month-fy26-performance","status":"publish","type":"post","link":"https:\/\/alphastreet.com\/india\/innova-captab-limited-accelerating-strategic-growth-with-strong-q3-and-9-month-fy26-performance\/","title":{"rendered":"Innova Captab Limited Accelerating Strategic Growth with Strong Q3 and 9-Month FY26 Performance"},"content":{"rendered":"\n<p>Innova Captab Limited (NSE: INNOVACAP\/BSE: 544067), is a leading integrated pharmaceutical company with a comprehensive business model spanning the entire value chain, including research and development, manufacturing, and marketing. The company serves as a preferred CDMO partner for prominent global pharmaceutical companies while maintaining a robust branded generics business in over 60 countries.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Q3 &amp; 9M FY26 Earnings Highlights<\/strong><\/h2>\n\n\n\n<p>The company delivered a stellar financial performance for the period.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Revenue from Operations: Surged by 42% YoY in Q3 FY26 to \u20b9450.3 crore and 27% YoY for 9M FY26 to \u20b91,182.2 crore.<\/li>\n\n\n\n<li>EBITDA: Grew by 40% YoY to \u20b971.1 crore in Q3 FY26, with margins at 15.8%.<\/li>\n\n\n\n<li>Profit After Tax (PAT): Increased by 23% YoY to \u20b942.1 crore for the quarter.<\/li>\n<\/ul>\n\n\n\n<p>Profitability metrics remained healthy despite expansion costs. EBITDA for Q3 FY26 rose 39.6% YoY to \u20b971.1 crore (15.8% margin), while 9M FY26 EBITDA reached \u20b9183.7 crore, growing 24.8%. Profit After Tax (PAT) for the quarter stood at \u20b942.1 crore (+23.2% YoY), bringing the 9M FY26 PAT to \u20b9102.8 crore, a 4.2% increase from the prior year.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"535\" src=\"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/Innova-2-1024x535.png\" alt=\"\" class=\"wp-image-177752\" srcset=\"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/Innova-2-1024x535.png 1024w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/Innova-2-300x157.png 300w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/Innova-2-768x401.png 768w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/Innova-2.png 1180w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Segment Performance Update<\/strong><\/h2>\n\n\n\n<p>The company&#8217;s growth was driven by diversified performance across its core segments.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>CDMO Services: Revenue for this segment grew 29% YoY in Q3 FY26 to \u20b9298.7 crore and 18% in 9M FY26 to \u20b9813.9 crore. This was fueled by deeper engagement with its base of 300+ global customers.<\/li>\n\n\n\n<li>Branded Generics: This vertical saw sharp growth of 79% in Q3 FY26 (\u20b9151.6 crore) and 56% in 9M FY26 (\u20b9368.4 crore), driven by expanded footprints in India and international markets.<\/li>\n\n\n\n<li>Export Mix: International contributions accounted for 35% of total revenue in Q3 FY26 and 32% across the 9M FY26 period.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Management Commentary<\/strong><\/h2>\n\n\n\n<p>Managing Director, Vinay Lohariwala attributed the results to &#8220;disciplined execution&#8221; and robust output across all manufacturing facilities. A major highlight was the receipt of GMP Compliance certifications from UK-MHRA for the Baddi facility and PIC\/s (SMDC, Ukraine) for the Jammu facility, which management views as a testament to their adherence to global quality standards.<\/p>\n\n\n\n<p>Management provided clear guidance for its Jammu Plant, which was commercialized in January 2025. ICL expects to ramp up capacity utilization at this state-of-the-art facility to optimum levels over the next 5-6 years. Furthermore, the company aims to unlock long-term synergies through the integration of Sharon Bio Medicine Ltd, particularly in Formulation and API offerings.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Broader Industry Trends<\/strong><\/h2>\n\n\n\n<p>The pharmaceutical industry is seeing a shift toward integrated players who can offer high-quality, affordable solutions at scale. Innova Captab is positioning itself to benefit from this by expanding its R&amp;D capabilities and leveraging the &#8220;New Central Sector Scheme&#8221; for industrial development in Jammu &amp; Kashmir, which provides GST-linked incentives and capital interest subventions.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Key Takeaway<\/strong> <\/h2>\n\n\n\n<p>Innova Captab&#8217;s Q3 and 9M FY26 performance reflects a successful transition into a high-growth phase. With the commercialization of the Jammu facility and a growing global footprint, the company is well-positioned to maintain consistent, high-quality growth while creating significant long-term stakeholder value.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Innova Captab Limited (NSE: INNOVACAP\/BSE: 544067), is a leading integrated pharmaceutical company with a comprehensive business model spanning the entire value chain, including research and development, manufacturing, and marketing. The company serves as a preferred CDMO partner for prominent global pharmaceutical companies while maintaining a robust branded generics business in over 60 countries. Q3 &amp; [&hellip;]<\/p>\n","protected":false},"author":2378,"featured_media":125416,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[5,1941,5747],"tags":[13743,1115,14609],"class_list":["post-177750","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-latest","category-stock-analysis","category-healthcare-stocks","tag-health-care","tag-pharmaceuticals","tag-results"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg","jetpack_likes_enabled":false,"jetpack-related-posts":[{"id":178128,"url":"https:\/\/alphastreet.com\/india\/innova-captab-q3-fy26-earnings-results\/","url_meta":{"origin":177750,"position":0},"title":"Innova Captab Q3 FY26 Earnings Results","author":"Divyansh_Kasana","date":"January 28, 2026","format":false,"excerpt":"Executive Summary Innova Captab Ltd reported Q3FY26 revenues of \u20b9450 crore, up 42.41% YoY, with consolidated net profit rising 23.53% to \u20b942 crore. Total expenses increased 44.0% YoY to \u20b9396 crore, reflecting strong revenue momentum despite cost pressures. Revenue & Growth Revenues jumped to \u20b9450.00 crore in Q3FY26 from \u20b9316.00\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/INNO.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/INNO.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/INNO.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/INNO.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/INNO.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/INNO.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":177745,"url":"https:\/\/alphastreet.com\/india\/innova-captab-limited-reports-robust-q3-fy26-results-revenue-surges-42-amid-global-expansion\/","url_meta":{"origin":177750,"position":1},"title":"Innova Captab Limited Reports Robust Q3 FY26 Results. Revenue Surges 42% Amid Global Expansion","author":"Staff Correspondent","date":"January 26, 2026","format":false,"excerpt":"Innova Captab Limited (NSE: INNOVACAP | BSE: 544067) announced its unaudited financial results for the third quarter and nine months ended December 31, 2025, on January 23, 2026. The company, a leading integrated pharmaceutical player, demonstrated a significant acceleration in revenue growth driven by its dual focus on Contract Development\u2026","rel":"","context":"In &quot;LATEST&quot;","block_context":{"text":"LATEST","link":"https:\/\/alphastreet.com\/india\/category\/latest\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/10\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/10\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/10\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":177762,"url":"https:\/\/alphastreet.com\/india\/innova-captab-limited-performance-market-environment-and-competitive-position\/","url_meta":{"origin":177750,"position":2},"title":"Innova Captab Limited Performance, Market Environment, and Competitive Position","author":"Staff Correspondent","date":"January 26, 2026","format":false,"excerpt":"Innova Captab Limited (NSE: INNOVACAP) has emerged as a noteworthy player in India's pharmaceutical landscape, combining contract development and manufacturing (CDMO) services with a branded generics business. In recent quarters, the company has delivered strong top-line growth coupled with improving profitability, reflecting both operational execution and expanding market reach. In\u2026","rel":"","context":"In &quot;LATEST&quot;","block_context":{"text":"LATEST","link":"https:\/\/alphastreet.com\/india\/category\/latest\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2022\/11\/tiny-pharmacist-with-pills-vitamins-flat-vector-illustration-doctors-writing-prescriptions-antibiotics-working-together-helping-patients-cure-pharmacy-business-drugstore-concept_74855-23225.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2022\/11\/tiny-pharmacist-with-pills-vitamins-flat-vector-illustration-doctors-writing-prescriptions-antibiotics-working-together-helping-patients-cure-pharmacy-business-drugstore-concept_74855-23225.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2022\/11\/tiny-pharmacist-with-pills-vitamins-flat-vector-illustration-doctors-writing-prescriptions-antibiotics-working-together-helping-patients-cure-pharmacy-business-drugstore-concept_74855-23225.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":179824,"url":"https:\/\/alphastreet.com\/india\/marksans-pharma-reports-q3fy26-with-revenue-growth-and-ebitda-margin-expansion\/","url_meta":{"origin":177750,"position":3},"title":"Marksans Pharma Reports Q3FY26 with Revenue Growth and EBITDA Margin Expansion","author":"Staff Correspondent","date":"February 6, 2026","format":false,"excerpt":"About Marksans Pharma Limited Marksans Pharma Limited (NSE: MARKSANS) is an Indian pharmaceutical company headquartered in Mumbai, India, founded in 1992. It specializes in the research, development, manufacturing and marketing of pharmaceutical formulations, offering both over-the-counter (OTC) and prescription medicines across various therapeutic areas such as pain management, cardiovascular health,\u2026","rel":"","context":"In &quot;Analysis&quot;","block_context":{"text":"Analysis","link":"https:\/\/alphastreet.com\/india\/category\/stock-analysis\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":179325,"url":"https:\/\/alphastreet.com\/india\/corona-q3-fy26-earnings-results\/","url_meta":{"origin":177750,"position":4},"title":"Corona Q3 FY26 Earnings Results","author":"Divyansh_Kasana","date":"February 3, 2026","format":false,"excerpt":"Executive Summary Corona Remedies Ltd reported Q3FY26 revenues of \u20b9342 crore, up 14.37% YoY, with consolidated net profit increasing 39.13% to \u20b964 crore despite higher expenses. Strong pharmaceutical demand drove topline growth while operational efficiencies supported margin expansion amid industry tailwinds. Revenue & Growth Revenues grew to \u20b9342 crore from\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/02\/COR.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/02\/COR.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/02\/COR.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/02\/COR.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/02\/COR.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/02\/COR.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":173228,"url":"https:\/\/alphastreet.com\/india\/srf-q3-fy26-earnings-results\/","url_meta":{"origin":177750,"position":5},"title":"SRF Q3 FY26 Earnings Results","author":"Chirag Gupta","date":"January 21, 2026","format":false,"excerpt":"Incorporated in 1970, SRF Ltd manufactures and sells technical textiles, chemicals, packaging films, aluminum foils, and other polymers. Q3 FY26 Earnings Results Gross Operating Revenue: \u20b93,712.5 crore, up 6.3% YoY from \u20b93,491.3 crore in Q3 FY25; up 1.99% QoQ from ~\u20b93,640 crore in Q2 FY26. Revenue from Operations: \u20b93,712.53 crore,\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"SRF Q3 FY26 Earnings Results","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/SRF-Q3-FY26-Earnings-Results.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/SRF-Q3-FY26-Earnings-Results.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/SRF-Q3-FY26-Earnings-Results.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/SRF-Q3-FY26-Earnings-Results.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/SRF-Q3-FY26-Earnings-Results.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/SRF-Q3-FY26-Earnings-Results.png?resize=1400%2C800&ssl=1 4x"},"classes":[]}],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/177750","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/users\/2378"}],"replies":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/comments?post=177750"}],"version-history":[{"count":1,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/177750\/revisions"}],"predecessor-version":[{"id":177753,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/177750\/revisions\/177753"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media\/125416"}],"wp:attachment":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media?parent=177750"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/categories?post=177750"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/tags?post=177750"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}